On September 2, 2026, Can-Fite Biopharma Ltd. entered into an inducement offer letter with a warrant holder to exercise existing warrants for up to 1,591,738 American Depositary Shares at a reduced price of $2.50 per ADS, generating approximately $4.0 million in gross proceeds. In consideration, the Company issued new warrants to purchase up to 3,183,476 ADSs at an exercise price of $2.50 per ADS. The transaction closed on September 3, 2026, with H.C. Wainwright & Co., LLC acting as placement agent for fees totaling approximately 8% plus expenses. Can-Fite Biopharma Ltd. operates in the biotechnology industry, developing therapies for inflammatory and fibrotic diseases.
